Experimental pill nearly doubles survival in advanced pancreatic cancer study
By Main Street Independent
A randomized clinical trial of 500 patients found the experimental daily pill daraxonrasib nearly doubled survival time for patients with advanced pancreatic cancer that had stopped responding to prior treatment.
Daraxonrasib blocks a mutated KRAS protein that fuels tumor growth in more than 90% of pancreatic cancer cases, a target that had eluded effective treatment for decades.
Patients receiving daraxonrasib experienced fewer severe side effects than those assigned to additional chemotherapy in the trial.
The New England Journal of Medicine published the findings, which researchers presented Sunday at the American Society for Clinical Oncology meeting in Chicago.
